Contrast Ultrasound

Phase 2Small molecule

RRabih A. Chaer

Contrast Ultrasound is one of 9 small molecule programs targeting Aortic Aneurysm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aortic AneurysmActive, not recruiting

Aortic AneurysmPhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Aortic Aneurysm

#DrugCompanyPhaseTrials

Diamox

Teva

Approved

1 2

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 3

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 2

—4

Perindopril Arginine

YYaounde Central Hospital

Phase 2

1 5

Cleviprex

Chiesi Farmaceutici S.p.A.

Preclinical

1 6

Sufenta

Contrast Ultrasound

1 8

Definity

MMicrovascular Therapeutics, LLC

Preclinical

1 9

Blood Taking

CCentre Hospitalier Universitaire de Besancon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aortic Aneurysm1 trial

Evaluation of Predictors of Aortic Aneurysm Growth and Rupture

Completed·RRabih A. Chaer·Phase 2·NCT02022436·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Contrast Ultrasound. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Contrast Ultrasound compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Contrast Ultrasound. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rabih A. Chaer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRabih A. Chaer

Contrast Ultrasound

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aortic Aneurysm1 trial

References

Drug Info

Quick Facts

Related News